Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

Rhea-AI Summary

Prelude Therapeutics (Nasdaq: PRLD), a clinical-stage precision oncology company, has announced its participation in the Barclays 27th Annual Global Healthcare Conference in Miami, FL on March 11, 2025.

Key executives participating in a fireside chat at 12:30 p.m. ET include:

• Kris Vaddi, Ph.D., Chief Executive Officer
• Jane Huang, M.D., President and Chief Medical Officer
• Bryant Lim, Chief Financial Officer

The event will be accessible via live webcast on the Company's website under Events and Presentations, with the recording remaining available for 90 days. Prelude Therapeutics specializes in developing innovative medicines for cancer patients, focusing on:

• First-in-class SMARCA2 degraders (IV and oral)
• CDK9 inhibitor development
• Precision ADCs (Degrader Antibody Conjugates) through partnerships

News Market Reaction – PRLD

+2.03%

+2.03% Session move

In the trading session that priced this news, PRLD gained 2.03%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WILMINGTON, Del., March 05, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays 27^th Annual Global Healthcare Conference, taking place in Miami, FL on March 11, 2025.

On Tuesday, March 11, 2025, at 12:30 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, Jane Huang, M.D., President and Chief Medical Officer, and Bryant Lim, Chief Financial Officer will participate in a fireside chat.

A live webcast of the fireside chat can be accessed on the Company’s website under Events and Presentations. The recording will be archived and available on the Company’s website for 90 days.

About Prelude Therapeutics 

Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective IV and oral SMARCA2 degraders, and a potentially best-in-class CDK9 inhibitor. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners. We are on a mission to extend the promise of precision medicine to every cancer patient in need. For more information, visit preludetx.com.

Investor Contact: 
Robert Doody
Senior Vice President, Investor Relations 
Prelude Therapeutics
484.639.7235
RDoody@preludetx.com

FAQ

When is Prelude Therapeutics (PRLD) presenting at the Barclays Healthcare Conference 2025?

Prelude Therapeutics will present on Tuesday, March 11, 2025, at 12:30 p.m. ET during a fireside chat at the Barclays Global Healthcare Conference in Miami.

What are the main drug candidates in Prelude Therapeutics' (PRLD) pipeline?

Prelude's pipeline includes first-in-class SMARCA2 degraders (both IV and oral), a CDK9 inhibitor, and Precision ADCs (degrader antibody conjugates) being developed through partnerships.

How long will the webcast of PRLD's Barclays conference presentation be available?

The webcast recording will be archived and available on Prelude Therapeutics' website for 90 days following the presentation.

Which executives from Prelude Therapeutics (PRLD) will participate in the Barclays conference?

CEO Kris Vaddi, Ph.D., President and CMO Jane Huang, M.D., and CFO Bryant Lim will participate in the fireside chat.

What therapeutic areas does Prelude Therapeutics (PRLD) focus on?

Prelude Therapeutics focuses on precision oncology, developing innovative medicines for cancer patients in areas of high unmet need.